pLenti6.2-ccdB-Nanoluc Citations (4)

Originally described in: Taipale Lab plasmids
Unpublished

---

Articles Citing pLenti6.2-ccdB-Nanoluc

Articles
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. Sci Signal. 2019 Sep 24;12(600). pii: 12/600/eaaw8288. doi: 10.1126/scisignal.aaw8288. PubMed
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096. PubMed
Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity. Wang J, Lu D, Yu X, Qi X, Lin H, Holloman BL, Jin F, Xu L, Ding L, Peng W, Wang M, Chen X. Res Sq [Preprint]. 2024 Apr 8:rs.3.rs-4156736. doi: 10.21203/rs.3.rs-4156736/v1. PubMed
Development of a RIPK1 degrader to enhance antitumor immunity. Yu X, Lu D, Qi X, Paudel RR, Lin H, Holloman BL, Jin F, Xu L, Ding L, Peng W, Wang MC, Chen X, Wang J. Nat Commun. 2024 Dec 16;15(1):10683. doi: 10.1038/s41467-024-55006-2. PubMed

If you have published an article using this material, please email us at to have your article added to this page.